

**Projects In
Knowledge®***At the Intersection of Knowledge
and Outcomes Since 1980*

Check Your CME/CE Tracker

Search

Go

Specialties/Topics

Cardiology
Dermatology
Diabetes
Endocrinology
Gastroenterology
Hematology
Infectious Diseases
Neurology
Oncology
Psychiatry
Pulmonology
Rheumatology
Women's Health

**Customize Your
Experience**
Customize Now



HOME » NEUROLOGY » CURRICULUM COURSE LIST

Multiple Sclerosis: The Advanced Curriculum

Expert Insight Into:

Placebo-Controlled Trial of an Oral Small Molecule for the Treatment of RRMS (Part 1 of Series)

Based on the Article:

Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366(11):1000-1009.
(Course MS05.01)Published on July 30, 2012 [Article Review](#)**Expert Faculty:** Fred D. Lublin, MD
Medical Writer: Carol Gorman, MS

This CME/CE activity has reached its termination date and no longer offers continuing education credit.
Please note that expired CME/CE activities may not contain the most up-to-date information available.

Click [here](#) to view our current activities in Neurology.

[Overview](#) | [Faculty](#)

NEXT

With the approval of an oral disease-modifying therapy for relapsing-remitting multiple sclerosis (RRMS), patients now have an effective alternative to injectable agents. A variety of other oral agents are currently in the later stages of development. One of these agents, laquinimod, has recently completed a phase III clinical trial. Join Dr. Lublin as he discusses the trial results and their implications for the management of RRMS.



Faculty
Fred D. Lublin, MD
Saunders Family Professor of
Neurology
The Corinne Goldsmith Dickinson
Center for Multiple Sclerosis
Mount Sinai School of Medicine
New York, NY

NEXT

Get Started

Multiple Sclerosis Curricula

Step 1

Select a topic ...

This independent CME/CE
activity is supported by an
educational grant from
Teva Neuroscience



Additional grant support from
Novartis Pharmaceuticals
Corporation, Allergan, and
Bayer HealthCare



Poll Question

In this study, a significant improvement in the mean annualized relapse rate was seen with laquinimod 0.6 mg/day compared with placebo. What proportion of patients receiving laquinimod remained relapse-free during the 24-month study?

- ☐ 52.2%
- ☐ 62.9%
- ☐ 79.5%
- ☐ 76.8%
- ☐ None of the above

Submit

RELATED ACTIVITIES

- [Journal Insights into: Phase III Trial Results for an Oral Sphingosine-1 Phosphate Receptor Modulator in Patients with RRMS](#)
- [Case Study #4: Treatment Decisions at Diagnosis and](#)

Google +

Recommend 0

Follow

2137.01

Cardiology
Dermatology
Diabetes
Endocrinology
Gastroenterology
Hematology
Infectious Diseases
Neurology
Oncology
Psychiatry
Pulmonology
Rheumatology
Women's Health

Trust In Knowledge
Educational Partners

Company News

Management
Accreditations
CEO's Message
Mission Statement
Meeting Posters

Home

Login/Register
Privacy Policy
Resources
Technical Requirements
Contact Us

[Breakthrough for Male Patients with Relapsing-Remitting MS Who Desire to Have Children](#)

- [Case Study #3: Management of Patients with Relapsing-Remitting MS and Worsening Disease on Interferon-Beta Therapy](#)

